Plasma cell-free DNA (cfDNA) profiling of copy number variation (CNV) to identify poor prognostic biomarkers in metastatic castration-resistant prostate cancer (mCRPC)

Edmond Michael Kwan; Heidi Fettke; Patricia Bukczynska; Nicole Ng; Christine Hauser; Lisa-Jane K Graham; Kate Lynette Mahon; Chao Dai; Feng Xie; Xiaohong Wang; Zhixin Zhao; Kemin Zhou; Peter Du; Jianjun Yu; Shidong Jia; Winston Tan; Lisa Horvath; Manish Kohli; Arun Azad

Conference Proceedings

Plasma cell-free DNA (cfDNA) profiling of copy number variation (CNV) to identify poor prognostic biomarkers in metastatic castration-resistant prostate cancer (mCRPC)

Edmond Michael Kwan, Heidi Fettke, Patricia Bukczynska, Nicole Ng, Christine Hauser, Lisa-Jane K Graham, Kate Lynette Mahon, Chao Dai, Feng Xie, Xiaohong Wang, Zhixin Zhao, Kemin Zhou, Peter Du, Jianjun Yu, Shidong Jia, Winston Tan, Lisa Horvath, Manish Kohli, Arun Azad

Journal of Clinical Oncology | AMER SOC CLINICAL ONCOLOGY | Published : 2020

DOI: 10.1200/jco.2020.38.6_suppl.176

Abstract

176 Background: Multiple tumour tissue studies have demonstrated the prognostic utility of CNVs in mCRPC. However, accurate assessment of CNVs in plasma cfDNA remains challenging, and prognostic significance has not been well characterized. Using a large customized panel, we correlated plasma CNVs with clinical outcomes in a contemporary cohort of mCRPC patients. Methods: Deep targeted sequencing was performed using a 180-gene cfDNA panel (Predicine) in 56 patients commencing AR pathway inhibitors (enzalutamide or abiraterone; n = 34) or taxane chemotherapy (n = 22) at two Australian institutions. Kaplan-Meier estimates and Cox proportional-hazards models were used to correlate CNVs with pr..

View full abstract